Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

A phase 1 dose-escalation with expansion study of the antibody-drug conjugate trastuzumab duocarmazine (SYD985) in locally advanced and metastatic solid tumours and HER2-expressing breast cancer

Banerji U. et al, (2019), The Lancet Oncology

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine-resistance in breast cancer

Morotti M. et al, (2019), Proceedings of the National Academy of Sciences of the United States of America

A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial

Thomas A. et al, (2018)

Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer

Lord SR. et al, (2018), Cell Metabolism

Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

Morotti M. et al, (2018), Eur J Drug Metab Pharmacokinet, 43, 137 - 153

Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer

Teoh EJ. et al, (2017), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S633 - S634

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).

Hall PS. et al, (2017), British journal of cancer, 116, 472 - 478

Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.

Mehta S. et al, (2016), EBioMedicine, 10, 109 - 116

Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality.

Lord S. et al, (2016), Curr Drug Targets, 17, 1714 - 1727

Window of opportunity studies: investigating the bioactivity of metformin in cancer

Lipplaa A. et al, (2015), Journal of Endocrinology, Diabetes and Obesity

Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?

Afshar M. et al, (2015), Cancer Investigation, 33, 347 - 353

Early phase cancer clinical trials: design, ethics and future directions.

Coupe N. et al, (2015), Br J Hosp Med (Lond), 76, 409 - 413

Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.

Lord SR. et al, (2015), J Natl Cancer Inst Monogr, 2015, 81 - 86

Imaging tumour hypoxia with positron emission tomography.

Fleming IN. et al, (2015), Br J Cancer, 112, 238 - 250

Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation.

Bensaad K. et al, (2014), Cell Rep, 9, 349 - 365

Gene expression and hypoxia in breast cancer.

Favaro E. et al, (2011), Genome Med, 3

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM

Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22, 31 - 31

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM

Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22

Cancer metabolism as a target for therapy

Lord SR. et al, (2011), MIMS Oncology

Angiogenesis - still a worthwhile target for breast cancer therapy?

Lord S. and Harris AL., (2010), Breast Cancer Res, 12 Suppl 4